Quarterly ResultAug 3, 2026, 06:56 AM
Indivior Q2 Revenue $343M, EPS $0.98; Raises FY26 Guidance; Supernus Merger
AI Summary
Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with Total Net Revenue increasing 14% year-over-year to $343 million and GAAP Net Income reaching $122 million. The company also significantly raised its full-year 2026 financial guidance for both Total Net Revenue and Adjusted EBITDA, driven by exceptional SUBLOCADE performance. Additionally, Indivior repurchased $175 million in shares during the quarter and reiterated its proposed merger with Supernus Pharmaceuticals is expected to close in Q4 2026.
Key Highlights
- Proposed merger with Supernus Pharmaceuticals expected to close in Q4 2026.
- Q2 2026 Total Net Revenue reached $343 million, a 14% increase year-over-year.
- Q2 2026 GAAP Net Income was $122 million, or $0.98 diluted earnings per share.
- Q2 2026 Adjusted EBITDA grew 111% year-over-year to $186 million.
- Full-year 2026 Total Net Revenue guidance raised to $1,295M-$1,365M.
- Full-year 2026 Adjusted EBITDA guidance raised to $700M-$740M.
- Repurchased 4.7 million shares for $175 million in Q2 2026.
- SUBLOCADE net revenue was $253 million in Q2 2026, up 21% year-over-year.
Price Impact
More from INDV